



## Life Settlement Assets PLC - Ordinary Share A

### **Investment Objective**

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

#### **Estimated Performance**



### Commentary

#### **Investment Terms**

1.5% Management Fee

Estimated NAV (USD) 107 445 339

NAV/Share 2.1564 200 longevity professionals attended the November 1st Fasano Longevity Conference in Washington, DC. The Conference focused on a wide range of topics bearing on longevity markets, mortality, and the economy. The Conference opened with research presentations focusing on the impact of gender and opioid on mortality. Latest research generated an extensive database of long-term care patients to share insights on the changes in mortality that occur as functional status declines. Further data augmentation using artificial intelligence and obituary research appears to have filled the death identification gap created by regulatory changes limiting the efficacy of the Master Death File.

The Share Class is reporting a disappointing performance of -0.91% for the month of October. Four HIV maturities were registered, contributing a total Death Benefit limited to \$0.2M; and only one maturity of \$0.02M was registered in the non-HIV segment this month. In addition, a small portfolio of fractionals, to which the trust was overwhelmingly already exposed to, was added to prevent any undue lapsing.


Number Of Policies	Death Benefits (USD)	Matured Policies YTD	Maturities YTD (USD)
4 368	468 356 198	1 11	31 167 633


Trust Investment Manager	Acheron Capital Ltd.	Company Secretary	ISCA Administration Services Limited
Administrator	Compagnie Européenne de Révision	ISIN Ticker	GB00BF1Q4B05 LSAA
Auditor	BDO UK LLP	Info	life@acheroncapital.com +44 207 258 5990


# October 2021












# October 2021








#### **Maturities October 2021**

Number of policies matured in October 2021	5
Corresponding number of insured	5
Total death benefit in October 2021 (US\$)	214 764
Valuation of Matured policies in Book (US\$)	43 526



### Premiums Situation (US\$) (1)

Servicers Premiums Projection for the next 12 months	\$ 15.8M
Mortality Adjusted Premiums Projection for the next 12 months	\$ 15.0M
Estimated COI Net of Mortality for the next 12 months	\$ 14.0M

### **Top 10 Coverage**

## op 10 Coverage

Insured	Face (millions)	Total Face (millions)	0	Expiration Age*
1	5.9/1.2	7.1	96	100/120
2	1.8/2.3/1.5	5.8	78	121/100/100
3	5.5	5.5	96	100
4	5.0	5.0	96	100
5	1.6/0.9/0.6/0.4/0.2	3.7	93	100/100/100/100/100
6	3.5	3.5	94	100
7	3.4	3.4	80	100
8	2.9	2.9	101	120
9	1.5/1.0/0.3	2.8	90	100/100/100
10	2.8	2.8	90	100

### Cash Situation (US\$) (1)

Cash at hand and similar	\$ 9.5M
Gross Cash in Policies <sup>(2)</sup> (estimated as of end 2020)	\$ 61.1M
Loan on Cash in Policies (estimated as of end 2020)	\$ 16.5M
Net Cash in Policies <sup>(2)</sup> (estimated as of end 2020)	\$ 44.6M
Maturities to be received	\$ 9.7M

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England. Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.

<sup>(1)</sup> Figures as provided by third parties

<sup>(2)</sup> Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Surrender charge included.

<sup>\*</sup>In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.